Enzolytics’s stock, took off on May 17th, and I’m really excited about this stock, ticker symbol, ENZC! This one would fit in well with Cathie Wood’s ARKG innovative Genomic revolution focus. Today we are going to dive into the details of Enzolytics, and if this would be a good one to help build your portfolio. I’m will cover the compelling aspects of this stock’s unique drug development approach, why their partnership with Intel is such as big deal, the state of their finances, then finally what analysts are projecting for this stock. I did spend hours poring through articles and financials on ENZC, to aid in a decision whether it made sense to buy this stock now, and if it is a good stock to hold onto for the long-term.
In the past I also spent years working with Fortune 500 CFOs to help them determine where they were making money, and now use this expertise to dig into Enzolytic’s details. But this is not financial advice, but for entertainment only.
First, a friendly reminder that if you enjoy today’s video, to hit the thumbs up button and leave a comment below.
Remember that Enzolytics is an OTC stock and therefore very risky as a good percentage of them fail. But we all look for the smaller percentage that have a huge run-up in price over the longer term!
Why am I so exciting about sharing Enzolytics with you? This company is part of the future of drug development and utilizes a 4P Medicine approach which is:
- Predictive – Our genetic makeup can predict the diseases we are at risk for.
- Preventative – Medicine that refocuses care on the future rather than the present.
- Personalized – Every human is genetically different and unique, and takes this into account as individuals transition from health to disease.
- It’s Participatory – which involves convincing physicians of the advantages of adopting newer technology, while educating patients about the opportunities, challenges, and responsibilities.
Enzolytics is a drug development company, that utilizes proprietary proteins for the treatment of debilitating infectious diseases. It has patented anti-HIV therapeutics and a proprietary methodology for producing human monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. Enzolytics has clinically tested its anti-HIV therapeutics. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus.
The May 17th news that had a big effect on this stock was about a white paper developed by Enzolytics and Intel, titled: “Optimizing Empathetic A.I. to Cure Deadly Diseases,”
Intel’s for years has been developing advanced Artificial Intelligence Analytic tools. Now Enzolytics is working with intel’s AI to create universal, durable, and broadly effective treatment targeting all virus variants.
The White Paper underscores Intel’s recognition of the premise of P4 Medicine and embraces Artificial Intelligence to deliver on the promise. Intel has made incredible advances in Artificial Intelligence’ applications to Empathetic A.I. They outsource healthcare tasks and decisions to rational machines, freeing up more time for healthcare professionals to provide patient care.
Intel’s Programmable Integrated Unified Memory Architecture (or PIUMA) and graph analytics will speed up drug discoveries and predictions about virus mutations.
Antibodies that broadly neutralize are necessary to provide effective therapy and prevention of disease. These applications leveraging a monoclonal antibody in immunotherapy are accomplished through Enzolytics’ proprietary method of producing neutralizing monoclonal antibodies. Now a primary focus is to create monoclonal antibodies that will universally neutralize the SARS-CoV-2 virus. Dr. Gaurav Chandra recognized A.I.’s potential and, based on knowledge of these homologous viral structures, targeting the corresponding “Achilles Heel” site on a virus.
Consequently, Dr. Chandra, COO and VP of Enzolytics R&D, worked with Denver Scientific’s genetics molecular biology data science team to screen more than 50,000 Coronavirus and 87,000 HIV isolates. Immutable sites on the SARS-CoV-2 virus have also been confirmed as existing (100%) in the U.S. SARS-CoV-2 virus variants that have surfaced in United Kingdom, Brazil, and South Africa.
The White Paper concluded that Enzolytics Inc’s use of Artificial Intelligence is a novel approach to assessing virus sequences and identifying the segments essential for virus survival.”
The power of A.I., coupled with advanced techniques in Enzolytics immunotherapeutics, have the potential to create broadly effective treatment targeting all virus variants.
So you can see why I’m so excited about Enzolytics, their partnership with Intel and their contributions to medicine.
I like to find early investment OTC Companies as they have lots of room to grow, but only if they have some encouraging areas of financial performance. I took a look at the Enzolytics’ profile, and you can see they are tiny, with a market cap of 326 Million, and as they have been sustaining losses, their PE ratio shows as Not applicable. I was very surprised by the heavy trading of this stock, reflected as an average daily volume of 40 million shares.
Their Yahoo financials also shows that this company is not yielding any cash from their operations. Etrade shows their 12-month stock performance as up 44,566%, but down 78% over the last 3 months!
For analysts targets for this stock, I searched TipRanks, Etrade, Finviz and the Nasdaq websites, and found nothing! My take on Enzolytics for now, is that it is a stock that I will watch for more progress in their work, financial growth and stability. Or, if you like to fund companies that have the potential to make a big impact on health, and want to do further research on it, that would make sense too. In the meantime, this stock appears to be a favorite of day traders.
Let me know if you own Enzolytics, what your thoughts are about this stock, or about other stocks you are linking right now. Also, if you found value, please give this video a thumbs-up and subscribe for more videos like this one!